Partial
Partially Aligned
Patient Risk:
Info
Summary
Partially aligned on general concept that Dayvigo (lemborexant) is an orexin receptor antagonist and that it treats adult insomnia with sleep onset and/or maintenance difficulties, but several statements are unsupported or go beyond the provided label excerpts (notably comparisons to other drugs/classes and the idea that other classes are 'typically' the closest match).
Category Scores
Accurate Statements
Dayvigo is a sleep medicine in the orexin receptor antagonist class.
Supported by label excerpt: 'DAYVIGO contains lemborexant, an orexin receptor antagonist.' (11 DESCRIPTION) and insomnia indication (1 INDICATIONS AND USAGE).
Dayvigo is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Supported by label excerpt: 'DAYVIGO is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.' (1 INDICATIONS AND USAGE).
Unsupported Statements
Drugs in the same class tend to be similar options because they work through the same sleep-wake pathway by blocking orexin signaling to help people fall asleep and stay asleep.
Not supported by the provided label excerpts; the excerpts describe lemborexant’s mechanism, but do not state cross-drug comparative similarity/treatment equivalence.
Belsomra (suvorexant) is an orexin receptor antagonist and is the main similar prescription medicine to Dayvigo.
The label excerpts provided do not mention Belsomra or make comparative statements about 'main similar' medicines.
Dayvigo is different from older sedative-hypnotics such as Ambien (zolpidem) and Lunesta (eszopiclone).
The provided excerpts do not discuss zolpidem/esozpiclone or compare mechanisms as stated.
Ambien (zolpidem) and Lunesta (eszopiclone) act mainly through GABA rather than blocking orexin.
The provided excerpts do not mention zolpidem/esozpiclone or their mechanism of action.
Orexin blockers, especially Belsomra, are typically the closest match if the goal is something like Dayvigo.
The label excerpts do not include comparative prescribing guidance or comparative 'closest match' statements.
Other medication categories for insomnia include sedative-hypnotics such as zolpidem/eszopiclone.
The provided excerpts do not mention insomnia medication categories or these specific comparators.
Other medication categories for insomnia include sedating antidepressants.
Not supported by the provided excerpts.
Other medication categories for insomnia include melatonin receptor agonists.
Not supported by the provided excerpts.
CBT-I is a non-drug option that is often used alongside or instead of medication.
The provided excerpts do not mention CBT-I or behavioral therapy guidance.
Contradictions
Important Omissions
Dose timing and dosing limits (e.g., 5 mg no more than once per night immediately before bed with at least 7 hours remaining; possible increase to 10 mg based on response/tolerability).
Importance:
Moderate
Key safety-related label elements that could be relevant when discussing 'sleep medicine' (e.g., contraindication in narcolepsy; CNS depressant effects and risk of next-day impairment; specific precautions about complex sleep behaviors).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Most statements are mechanism/comparison/general category claims not directly grounded in the provided label excerpts; potential risk is primarily from unsupported comparative guidance ('main similar', 'closest match', and category assertions) rather than direct dosing or contraindication misstatements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims about other drugs/classes (zolpidem/esozpiclone, Belsomra) and comparative/typical prescribing guidance are not supported by the provided Dayvigo label excerpts.
Suggested Improvement
Restrict statements to what is explicitly supported in the provided label excerpts (e.g., Dayvigo’s orexin antagonist mechanism, insomnia indication, and the label’s dosing and key safety/contraindication information). Avoid comparative assertions like 'main similar' or 'closest match' unless directly supported by the provided label text.